Management of radioiodine ablation therapy in haemodialysis patients with thyroid cancer: a case series of two patients
Abstract Background Radioiodine (131I) therapy in treatment of thyroid cancer, has a biological clearance that is significantly reduced in end-stage kidney disease (ESKD), leading to increased radiation exposure and potential myelotoxicity. For ESKD patients on haemodialysis (HD), there is no standa...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2025-07-01
|
| Serie: | BMC Nephrology |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12882-025-04348-0 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|